Chemoproteogenomic stratification of the missense variant cysteinome

Heta Desai, Katrina H. Andrews, Kristina V. Bergersen, Samuel Ofori, Fengchao Yu, Flowreen Shikwana, Mark A. Arbing, Lisa M. Boatner, Miranda Villanueva, Nicholas Ung, Elaine F. Reed, Alexey I. Nesvizhskii and Keriann M. Backus ()
Additional contact information
Heta Desai: UCLA
Katrina H. Andrews: UCLA
Kristina V. Bergersen: UCLA
Samuel Ofori: UCLA
Fengchao Yu: University of Michigan
Flowreen Shikwana: UCLA
Mark A. Arbing: UCLA
Lisa M. Boatner: UCLA
Miranda Villanueva: UCLA
Nicholas Ung: UCLA
Elaine F. Reed: UCLA
Alexey I. Nesvizhskii: University of Michigan
Keriann M. Backus: UCLA

Nature Communications, 2024, vol. 15, issue 1, 1-24

Abstract: Abstract Cancer genomes are rife with genetic variants; one key outcome of this variation is widespread gain-of-cysteine mutations. These acquired cysteines can be both driver mutations and sites targeted by precision therapies. However, despite their ubiquity, nearly all acquired cysteines remain unidentified via chemoproteomics; identification is a critical step to enable functional analysis, including assessment of potential druggability and susceptibility to oxidation. Here, we pair cysteine chemoproteomics—a technique that enables proteome-wide pinpointing of functional, redox sensitive, and potentially druggable residues—with genomics to reveal the hidden landscape of cysteine genetic variation. Our chemoproteogenomics platform integrates chemoproteomic, whole exome, and RNA-seq data, with a customized two-stage false discovery rate (FDR) error controlled proteomic search, which is further enhanced with a user-friendly FragPipe interface. Chemoproteogenomics analysis reveals that cysteine acquisition is a ubiquitous feature of both healthy and cancer genomes that is further elevated in the context of decreased DNA repair. Reference cysteines proximal to missense variants are also found to be pervasive, supporting heretofore untapped opportunities for variant-specific chemical probe development campaigns. As chemoproteogenomics is further distinguished by sample-matched combinatorial variant databases and is compatible with redox proteomics and small molecule screening, we expect widespread utility in guiding proteoform-specific biology and therapeutic discovery.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-53520-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-53520-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-53520-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().